Recent coverage of Option Care Health (OPCH) has focused on its valuation metrics, which compare favorably with industry averages, along with references to an earnings outlook that has drawn fresh attention from value oriented investors.

At a latest share price of US$23.70, Option Care Health has recorded a 30 day share price return of 12.06% and a 90 day share price return of 13.23%, although the year to date share price return is down 26.49% and the 1 year total shareholder return is down 17.54%. This points to some recent momentum but a weaker longer term record.

If you are weighing Option Care Health against other opportunities in the sector, this could be a useful moment to scan for healthcare related growth stories through the 41 healthcare AI stocks.

Bulls point to Option Care Health’s valuation ratios and earnings outlook after the recent rebound, while bears focus on the weaker multiyear return record. Which side does the current valuation evidence support next?

Most Popular Narrative: 17.1% Undervalued

Option Care Health’s most followed valuation narrative points to a fair value of $28.58 versus the latest share price of $23.70, framing the stock as modestly undervalued and tying that gap to the company’s specialty infusion focus and earnings outlook.

Growth in both acute and chronic infusion therapies is outpacing the market, driven by demographic shifts (aging population and higher prevalence of chronic/complex conditions), which is expanding Option Care Health's addressable market and positioning the company for sustained revenue growth.

Read the complete narrative. Read the complete narrative.

Want to see what sits behind that valuation gap? The narrative leans heavily on steady revenue expansion, firmer profit margins, and a future earnings multiple below broader healthcare. Curious which specific growth and margin assumptions support that $28.58 fair value.

Result: Fair Value of $28.58 (UNDERVALUED)

However, there are still therapy mix and reimbursement risks for Option Care Health that could weigh on margins and challenge the 17.1% undervaluation narrative.

Another View on Option Care Health’s Value

The analyst narrative frames Option Care Health as 17.1% undervalued versus a fair value of US$28.58, based on earnings forecasts and a future P/E of 16.8x. Our DCF model tells a different story. It suggests a value of US$18.08, which makes the current US$23.70 share price look expensive and raises questions about how reliable long dated earnings assumptions might be.

Investors who want to see how this alternative approach works in practice can review how the SWS DCF model is built and stress test their own assumptions through the Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Option Care Health for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 48 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals on Option Care Health so far, this is a useful time to move quickly, review the details, and weigh both sides of the story through the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Option Care Health?

If Option Care Health has sharpened your focus, do not stop here. Use the Simply Wall Street Screener to uncover other focused opportunities that fit your checklist.

• Target stability with companies that combine resilient cash flows and conservative leverage through the solid balance sheet and fundamentals stocks screener (50 results).
• Hunt for mispriced opportunities by scanning for companies that look attractively priced relative to fundamentals using the 48 high quality undervalued stocks.
• Strengthen your income stream by spotting companies with higher yields and consistent payouts via the 12 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.